Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cancers|April 23, 2022
Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. <i>Cancers</i> 2020, <i>12</i>, 2447Gil Bar-Sela, Idan Cohen, Salvatore Campisi-Pinto, et al.
The Oncologist|March 19, 2022
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world DataMor Moskovitz, Elizabeth Dudnik, Sivan Shamai, et al.
JTO Clinical and Research Reports|April 22, 2026
Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World StudySameh Daher, Walid Shalata, Natali Shirron, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2025
Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomesBelal Krayim, Walid Shalata, Jair Bar, et al.
Frontiers in Oncology|June 1, 2022
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs)Ari Raphael, Amir Onn, Liran Holtzman, et al.
Clinical Lung Cancer|December 4, 2016
ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous ThromboembolismAlona Zer, Mor Moskovitz, David M Hwang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2017
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Mor Moskovitz, Sameh Daher, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2025
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumabFrancesco Cortiula, Talia Shentzer Kutiel, Melinda L Hsu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2018
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Nir Peled, Hovav Nechushtan, et al.
Clinical Lung Cancer|January 14, 2017
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 PatientsMichal Sarfaty, Assaf Moore, Victoria Neiman, et al.
Pageof 5